Mechanistic Evaluation of the Pros and Cons of Digital RT-LAMP for HIV-1 Viral Load Quantification on a Microfluidic Device and Improved Efficiency via a Two-Step Digital Protocol
Abstract
Here we used a SlipChip microfluidic device to evaluate the performance of digital reverse transcription-loop-mediated isothermal amplification (dRT-LAMP) for quantification of HIV viral RNA. Tests are needed for monitoring HIV viral load to control the emergence of drug resistance and to diagnose acute HIV infections. In resource-limited settings, in vitro measurement of HIV viral load in a simple format is especially needed, and single-molecule counting using a digital format could provide a potential solution. We showed here that when one-step dRT-LAMP is used for quantification of HIV RNA, the digital count is lower than expected and is limited by the yield of desired cDNA. We were able to overcome the limitations by developing a microfluidic protocol to manipulate many single molecules in parallel through a two-step digital process. In the first step we compartmentalize the individual RNA molecules (based on Poisson statistics) and perform reverse transcription on each RNA molecule independently to produce DNA. In the second step, we perform the LAMP amplification on all individual DNA molecules in parallel. Using this new protocol, we increased the absolute efficiency (the ratio between the concentration calculated from the actual count and the expected concentration) of dRT-LAMP 10-fold, from 2% to 23%, by (i) using a more efficient reverse transcriptase, (ii) introducing RNase H to break up the DNA:RNA hybrid, and (iii) adding only the BIP primer during the RT step. We also used this two-step method to quantify HIV RNA purified from four patient samples and found that in some cases, the quantification results were highly sensitive to the sequence of the patient's HIV RNA. We learned the following three lessons from this work: (i) digital amplification technologies, including dLAMP and dPCR, may give adequate dilution curves and yet have low efficiency, thereby providing quantification values that underestimate the true concentration. Careful validation is essential before a method is considered to provide absolute quantification; (ii) the sensitivity of dLAMP to the sequence of the target nucleic acid necessitates additional validation with patient samples carrying the full spectrum of mutations; (iii) for multistep digital amplification chemistries, such as a combination of reverse transcription with amplification, microfluidic devices may be used to decouple these steps from one another and to perform them under different, individually optimized conditions for improved efficiency.
Additional Information
© 2013 American Chemical Society. Received: September 20, 2012; Accepted: December 27, 2012; Published: January 16, 2013. This work was supported by NIH Grant R01EB012946 administered by the National Institute of Biomedical Imaging and Bioengineering and by the NIH Director's Pioneer Award program, part of the NIH Roadmap for Medical Research (5DP1OD003584). We thank Bridget Samuels for contributions to writing and editing this manuscript. We thank Dr. Loren Joseph and Dr. Reddy Poluru for providing RNA purified from patient samples.Attached Files
Accepted Version - nihms-436938.pdf
Supplemental Material - ac3037206_si_001.pdf
Files
Name | Size | Download all |
---|---|---|
md5:8ef3bd1225c5bd3d547562d8f6978be6
|
1.4 MB | Preview Download |
md5:abaa5269f11f023b4e6e52db700f7dd6
|
412.3 kB | Preview Download |
Additional details
- PMCID
- PMC3578705
- Eprint ID
- 37579
- Resolver ID
- CaltechAUTHORS:20130320-140730972
- NIH
- R01EB012946
- NIH
- 5DP1OD003584
- Created
-
2013-04-01Created from EPrint's datestamp field
- Updated
-
2021-11-09Created from EPrint's last_modified field